Clinical Trial

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open label, single-dose study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CD34+ Human Hematopoietic Stem Cells that was transduced with LentiRed Lentivrial vector.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-28.
Trial Details
NCT Number NCT05762510
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Collaborators: Genmedicn Biopharma Ltd.
Conditions Transfusion Dependent Beta-Thalassemia
Enrollment 5 participants
Start Date 2023-02-22
Primary Completion 2028-04-01 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-09